Methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate(CAS: 50-55-5)

Methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate (CAS: 50-55-5) is a complex organic compound with a quinolizidine alkaloid backbone. It contains multiple methoxy groups and a trimethoxybenzoyl moiety, making it a derivative of yohimbine. Its molecular structure is characterized by ester functionality and specific stereochemistry at key positions. This compound is primarily used in research and pharmaceutical development for its potential biological activities.

This compound is mainly used in pharmaceutical research for studying its pharmacological properties, particularly in relation to alpha-2 adrenergic receptor modulation. It also serves as a key intermediate in the synthesis of drugs targeting erectile dysfunction, obesity, and cardiovascular conditions. Additionally, it is utilized in biochemical studies to explore its potential therapeutic applications and structural modifications.

Safety of this compound depends on its handling and application. As a chemical derivative, it may exhibit similar toxicity profiles to yohimbine, including potential effects on the cardiovascular system. Precautions include wearing protective gloves, goggles, and clothing to avoid skin contact. It should be handled in well-ventilated areas and stored according to recommended guidelines to ensure safety during research and industrial use.

This compound should be stored in a cool, dry place, away from direct light, in a sealed, airtight container. Maintain storage conditions between 2-8°C to preserve stability. Avoid exposure to moisture and incompatible substances. Proper labeling and adherence to chemical safety standards are essential to ensure long-term storage and prevent degradation.